FrancophonIA/ELRC3.0 huggingface dataset:
English: Treatment effects in other evaluable subgroups (e.g. age, gender, race, baseline visual acuity, CRVO duration) in each study were in general consistent with the results in the overall populations.
Maltese: Effetti tat-trattament f'sottogruppi oħra li setgħu jiġu evalwati (eż. età, sess, razza, akutezza viżiva fil-linja bażi, dewmien ta' CRVO) f'kull studju b'mod ġenerali kienu konsistenti mar-riżultati fil-popolazzjonijiet globali.
English: Marketing Authorisation Holder Bayer AG
Maltese: Detentur tal-Awtorizzazzjoni għat-Tqegħid fis-Suq Bayer AG
English: ALTAIR was a 96 week multicentre, randomised, open-label study in 247 Japanese patients with treatment naïve wet AMD, designed to assess the efficacy and safety of Eylea following two different adjustment intervals (2-weeks and 4-weeks) of a treat-and-extend dosing regimen.
Maltese: ALTAIR kien studju ta' 96 ġimgħa b'ħafna ċentri, randomised, open-label fuq 247 pazjent Ġappuniż b'AMD imxarrba li qatt ma rċevew trattament qabel, maħsub biex jevalwa l-effikaċja u s-sigurtà ta' Eylea wara żewġ intervalli ta' aġġustament differenti (ġimagħtejn u 4 ġimgħat) ta' kors ta' dożaġġ ta' ittratta u estendi.
English: For the intravitreal injection, a 30 G x ½ inch injection needle should be used.
Maltese: Għall-injezzjoni ġol-vitriju għandha tintuża labra tal-injezzjoni ta' 30 G x ½ pulzier.
English: As with other large proteins, both free and bound aflibercept are expected to be cleared by proteolytic catabolism.
Maltese: Bħal ma bi proteini kbar oħra, kemm aflibercept ħieles kif ukoll dak marbut huma mistennija li jitneħħew permezz ta' kataboliżmu proteolitiku.
English: • Risk factors associated with the development of a retinal pigment epithelial tear after antiVEGF therapy for wet AMD, include a large and/or high pigment epithelial retinal detachment.
Maltese: • Fatturi ta' riskju assoċjati mal-iżvilupp ta' tiċrita tal-epitelju tal-pigment tar-retina wara terapija kontra VEGF għal AMD imxarrba, jinkludu qtugħ kbir u/jew il-fuq tal-epitilju tal-pigment tarretina.
English: After your injection with Eylea, you may experience some temporary visual disturbances.
Maltese: Wara l-injezzjoni tiegħek b'Eylea jista' jkollok xi disturbi temporanji fil-vista.
English: • Sterile techniques, including periocular and ocular disinfection to minimise the risk of infection
Maltese: • Tekniki sterili, inkluż disinfettar madwar l-għajn u tal-għajn sabiex jitnaqqas ir-riskju ta'
English: VEGF levels are elevated in response causing the leakage of fluid into the retina and thereby causing a swelling of the macula, (the portion of the retina responsible for fine vision), which is called macular oedema.
Maltese: B'riżultat ta' dan il-livelli ta' VEGF jiżdiedu u jwasslu għal tnixxija ta' fluwidu fir-retina u b'hekk jikkawżaw nefħa tal-makula, (il-parti tar-retina responsabbli għall-vista dettaljata), li tissejjaħ edima makulari.
English: One pre-filled syringe delivers a dose of 2 mg aflibercept in 50 microlitres.
Maltese: Id-doża rakkomandata ta' Eylea hija ta' 2 mg aflibercept ekwivalenti għal 50 mikrolitru.
English: Furthermore, it is important for you to know that:
Maltese: Medja ta' LS:
English: EMEA/459391/2008-EN
Maltese: EMEA/459391/2008-MT
English: London, August 2008 EMEA/459391/2008
Maltese: Londra, Awwissu 2008 EMEA/459391/2008
English: Compagel Gel for Horses contains heparin sodium, levomenthol and hydroxyethyl salicylates.
Maltese: Il-Ġel għaż-Żwiemel Compagel fih heparin sodium, levomenthol u hydroxyethyl salicylates.
English: The CVMP Opinion was adopted on 13 February 2008 and the subsequent Commission Decision on 2 April 2008.
Maltese: L-Opinjoni tas-CVMP ġiet adottata fit-13 ta' Frar 2008 u d-Deċiżjoni sussegwenti tal-Kummissjoni fit-2 ta' April 2008.
English: OPINION FOLLOWING AN ARTICLE 33 (4) REFERRAL FOR COMPAGEL GEL FOR HORSES
Maltese: OPINJONI WARA RIFERIMENT SKONT L-ARTIKOLU 33 (4)
English: • Haematoma, tendinitis, tendovaginitis, bursitis, capped hock, saddle sore, sprain, torsion,
Maltese: • Ematoma, tendinite, tendovaġinite, bursite, infjammazzjoni tal-irkoppa (capped hock), uġigħ minħabba s-sarġ (saddle sore), liwi, torsjoni, kontużjoni, tbenġil, infjammazzjoni tal-kapsula tal ġog (sinovite), tiċrit ta' muskoli, sitwazzjonijiet ta' wara l-anesteżija bl-imblokk tan-nervituri,
English: • To accelerate the absorption of infiltrates (e.g. postoperative swelling, penile paralysis).
Maltese: • Biex jaċċelera l-assorbiment ta' infiltrati (eż. infiħ postoperattiv, paraliżi tal-pene).
English: In June 2007 a mutual recognition procedure started with Germany as Reference Member State and 5 Concerned Member States.
Maltese: F'Ġunju 2007 nbdiet proċedura ta' għarfien reċiproku bil-Ġermanja bħala Stat Membru ta' Referenza u 5
English: The CVMP started the referral procedure during its meeting of 15-17 January 2008.
Maltese: Is-CVMP beda l-proċedura ta' riferiment waqt il-laqgħa tiegħu ta' bejn il-15 u s-17 ta' Jannar 2008.
English: Having considered the referral notification and responses of the applicant, the CVMP concluded that all concerned member states in the mutual recognition procedure agreed that Compagel Gel for Horses is essentially similar to Tensolvet 50000.
Maltese: Wara li qies in-notifika tar-riferiment u t-tweġibiet tal-applikant, is-CVMP ikkonkluda li l-Istati Membri kollha kkonċernati fil-proċedura ta' għarfien reċiproku qablu li l-Ġel għaż-Żwiemel Compagel huwa essenzjalment simili għal Tensolvet 50000.
English: • To treat inflammations of superficial veins (e.g. phlebitis, thrombophlebitis, infusion thrombophlebitis).
Maltese: • Biex jittratta l-infjammazzjonijiet tal-vini superfiċjali (eż. flebite, tromboflebite, tromboflebite tal infużjoni).
English: The matter was referred to the Co-ordination Group for Mutual Recognition and Decentralised Procedures CMD(v) and subsequently to the CVMP.
Maltese: Il-kwistjoni ġiet riferuta lill-Grupp ta' Koordinazzjoni għall-Għarfien Reċiproku u Proċeduri Deċentralizzati CMD(v) u sussegwentament lisCVMP.
English: No differences between the two products have been identified that would justify different conclusions on the safety and efficacy.
Maltese: bejn iż-żewġ prodotti li tista' tiġġustifika konklużjonijiet differenti dwar is-sigurtà u l-effikaċja.
English: The Marketing Authorisation Holder was requested to provide a copy of the dossier and, in view of the concerns raised by France and Sweden, to indicate and to substantiate where necessary any differences between Compagel Gel for Horses and the reference product that could justify different conclusions on the safety or efficacy for the two products.
Maltese: Id-Detentur tal-Awtorizzazzjoni għat-Tqegħid fis-Suq intalab jipprovdi kopja tad-dokumentazzjoni u, fid-dawl tat-tħassib imqajjem minn Franza u l-Iżvezja, biex jindika u jissostanzja fejn meħtieġ xi differenzi li jista' jkun hemm bejn il-Ġel għaż-Żwiemel Compagel u l-prodott ta' referenza li jistgħu jiġġustifikaw konklużjonijiet differenti dwar is-sigurtà u l-effikaċja taż-żewġ prodotti.
English: France and Sweden could not agree to the granting of a marketing authorisation as they considered there were potential serious risks to animal health.
Maltese: Franza u l-Iżvezja ma setgħux jaqblu fuq l-għoti ta' awtorizzazzjoni għat-tqegħid fis-suq għax qiesu li kien hemm riskji serji potenzjali għas-saħħa tal-annimali.
English: Compagel Gel for Horses is a generic product.
Maltese: Il-Ġel għaż-Żwiemel Compagel huwa prodott ġeneriku.
English: Bottle (LDPE)
Maltese: Flixkun (LDPE) tond
English: Bottle (LDPE) oval
Maltese: Flixkun (LDPE) 5 ml
English: MA (EU) number (Invented) name Strength Pharmaceutical Form
Maltese: Numru tal-EU (MA)
English: It may harm them,
Maltese: Ġeneru sesswali u anzjani
English: 3 (11.0 % versus 0.9 %).
Maltese: 3 (11.0% kontra 0.9%).
English: Interferons (pegylated interferons alfa 2a and alfa 2b)
Maltese: Interferons (pegylated interferons alfa 2a u alfa 2b)
English: SN {number} [serial number]
Maltese: SN {numru} [numru tas-serje]
English: Total cholesterol.
Maltese: Kolesterol totali.
English: Total cholesterol/HDL
Maltese: Kolesterol totali/HDL
English: 17.9 to 31.2
Maltese: 17.9 sa 31.2
English: Date of latest renewal: 20 December 2012
Maltese: Data tal-aħħar tiġdid: 20 ta' Diċembru 2012
English: ANTACIDS Cimetidine
Maltese: ANTAĊIDI Cimetidine
English: Lactose (as monohydrate)
Maltese: Lactose (bħala monohydrate)
English: - Africa
Maltese: - Afrika
English: 31.3 to 43.7
Maltese: 31.3 sa 43.7
English: Y181C, K101E, G190A/S, K103N, V106A/M, V108I, Y188C/L, A98G, F227L and M230L.
Maltese: Y181C, K101E, G190A/S, K103N, V106A/M, V108I, Y188C/L, A98G, F227L u M230L
English: - Death - Adverse events
Maltese: - Mewt - Avvenimenti avversi
English: 25 and above
Maltese: 25 u iżjed
English: INTEGRASE INHIBITORS Elvitegravir/ cobicistat
Maltese: IMPEDITURI TA' INTEGRASE Elvitegravir/ cobicistat
English: No clinical data available.
Maltese: L-ebda data klinika mhi disponibbli.
English: - The active substance is nevirapine.
Maltese: - Is-sustanza attiva hi nevirapine.
English: Nevirapine is a NNRTI of HIV-1.
Maltese: Nevirapine huwa NNRTI ta' HIV-1.
English: 43.8 and above
Maltese: 43.8 u iżjed
English: PC {number} [product code]
Maltese: PC {numru} [kowd tal-prodott]
English: Boceprevir is partly metabolized by CYP3A4/5.
Maltese: Boceprevir jiġi metabolizzat parzjalment minn CYP3A4/5.
English: The geometric mean nevirapine Cmin,ss was 2,770 ng/ml.
Maltese: Il-medja ġeometrika ta' nevirapine Cmin,ss kienet ta' 2,770 ng/ml.
English: ANTIBIOTICS Clarithromycin 500 mg BID
Maltese: ANTIBIJOTIĊI Clarithromycin 500 mg BID
English: Virologic responder (HIV-1 RNA <50 copies/ml)
Maltese: Responder viroloġiku (HIV-1 RNA <50 kopji/ml)
English: CONTRACEPTIVES Depomedroxyprogesterone acetate (DMPA) 150 mg every 3 months
Maltese: KONTRAĊETTIVI Depomedroxyprogesterone acetate (DMPA) 150 mg kull 3 xhur
English: 2NN study
Maltese: Studju 2NN
English: HIV-1 subtype
Maltese: 3 b'HIV-1
English: - The other ingredients are: microcrystalline cellulose, lactose (as monohydrate), povidone K25, sodium starch glycolate, colloidal silicon dioxide and magnesium stearate.
Maltese: Microcrystalline cellulose, Lactose (bħala monohydrate) Povidone K25, Sodium starch glycolate, Colloidal silicon dioxide Magnesium stearate.
English: ANTIVIRALS FOR CHRONIC HEPATITIS B AND C Adefovir
Maltese: ANTIVIRALI GĦAL EPATITE B U Ċ KRONIKA Adefovir
English: Frequency is defined using the following convention: very common (1/10); common (1/100 to <1/10); uncommon (1/1,000 to <1/100); rare (1/10,000 to <1/1,000); very rare (<1/10,000)
Maltese: Il-frekwenza hija mfissra permezz tal-konvenzjoni li ġejja: komuni ħafna (1/10); komuni (1/100 sa <1/10); mhux komuni (1/1,000 sa <1/100); rari (1/10,000 sa <1/1,000); rari (<1/10,000)
English: PHARMACEUTICAL FORM AND CONTENTS 240 ml oral suspension
Maltese: GĦAMLA FARMAĊEWTIKA U KONTENUT 240 ml suspensjoni orali
English: Viramune contains lactose and sodium
Maltese: Viramune fih lactose u sodium
English: EU/1/97/055/003 [120 tablets]
Maltese: EU/1/97/055/003 [120 pillola]
English: The consolidated analysis of Paediatric AIDS Clinical Trials Group (PACTG) protocols 245, 356, 366, 377, and 403 allowed for the evaluation of paediatric patients less than 3 months of age (n=17) enrolled in these PACTG studies.
Maltese: L-analiżi konsolidata ta' protokolli 245, 356, 366, 377, u 403 tal-Paediatric AIDS Clinical Trials Group (PACTG) ippermettew għall-evalwazzjoni ta' pazjenti pedjatri li għandhom anqas minn 3 xhur (n=17) reklutati f'dawn l-istudji ta' PACTG.
English: 3 in adult females and >400/mm
Maltese: 3 f'nisa adulti u >400/mm
English: BSA range (m
Maltese: BSA (m
English: Nevirapine Cmax  0.50 compared to historical controls.
Maltese: Nevirapine Cmax  0.50 meta mqabbel ma' kontrolli storiċi.
English: ANTI-INFECTIVES ANTIRETROVIRALS NRTIs
Maltese: MEDIĊINI KONTRA L-INFEZZJONIJIET ANTIRETROVIRALI
English: Table 2 describes week 48 outcomes in the VERxVE study (1100.1486).
Maltese: Tabella 2 tiddeskrivi r-riżultati wara 48 ġimgħa fi studju VERxVE (1100.1486).
English: HERBAL PRODUCTS St. John's Wort
Maltese: John's Wort St.
English: Nevirapine Cmax  1.24 compared to historical controls.
Maltese: Nevirapine Cmax  1.24 meta mqabbel ma' kontrolli storiċi.
English: Nevirapine is an inducer of CYP3A and potentially CYP2B6, with maximal induction occurring within 2-4 weeks of initiating multiple-dose therapy.
Maltese: Nevirapine huwa induttur ta' CYP3A u potenzjalment ta' CYP2B6, b'induzzjoni massima li sseħħ fi żmien 2-4 ġimgħat mill-bidu ta' terapija b'diversi dożi.
English: Lopinavir/ritonavir (oral solution) 300/75 mg/m2 BID
Maltese: Lopinavir/ritonavir (soluzzjoni orali) 300/75 mg/m2 BID
English: Maintenance packs
Maltese: Pakketti ta' manteniment
English: Nevirapine: plasma levels:  1.151.28 compared to historical controls.
Maltese: Livelli ta' nevirapine fil-plażma:  1.15-1.28 meta mqabbla ma' kontrolli storiċi.
English: Each ml of oral suspension contains 150 mg sucrose, 162 mg sorbitol, 1.8 mg of methyl parahydroxybenzoate and 0.24 mg of propyl parahydroxybenzoate.
Maltese: Kull ml ta' suspensjoni orali fiha 150 mg sukkrosju, 162 mg sorbitol, 1.8 mg ta' methyl parahydroxybenzoate u 0.24 mg ta' propyl parahydroxybenzoate.
English: Mosteller Formula: BSA (m
Maltese: Medda BSA (m
English: Nevirapine had a median EC50 value (50% inhibitory concentration) of 63 nM against a panel of group M HIV-1 isolates from clades A, B, C, D, F, G, and H, and circulating recombinant forms (CRF), CRF01_AE, CRF02_AG and CRF12_BF replicating in human embryonic kidney 293 cells.
Maltese: Nevirapine kellu valur medjan ta' EC50 (50% konċentrazzjoni inibitorja) ta' 63 nM fuq kampjuni minn panew ta' HIV-1 minn grupp M minn clades A, B, C, D, F, G, u H u l-għamliet rikombinanti li jiċċirkolaw (CRF), CRF01_AE, CRF02_AG u CRF12_BF li jirreplikaw fiċ-ċelluli 293 tal-kilwa embrijonika umana.
English: INFORMATION IN BRAILLE Viramune 50 mg/5 ml
Maltese: Viramune 50 mg/5 ml
English: Metabolite 25-O-desacetylrifabutin AUC  1.24 (0.84-1.84) Metabolite 25-O-desacetylrifabutin Cmin  1.22 (0.86-1.74) Metabolite 25-O-desacetylrifabutin Cmax  1.29 (0.98-1.68)
Maltese: Metabolit 25-O-desacetylrifabutin AUC  1.24 (0.84-1.84) Metabolit 25-O-desacetylrifabutin Cmin  1.22 (0.86-1.74) Metabolit 25-O-desacetylrifabutin Cmax  1.29 (0.98-1.68)
English: Lopinavir/ritonavir (capsules) 400/100 mg BID
Maltese: Lopinavir/ritonavir (kapsuli) 400/100 mg BID
English: Cartons containing 6 or 12 blister cards (60 or 120 tablets).
Maltese: Kartun li fihom 6 jew 12-il strixxa (60 jew 120 pillola).
English: ANTIFUNGALS Fluconazole 200 mg QD
Maltese: ANTIFUNGALI Fluconazole 200 mg QD
English: Recommended paediatric dosing by BSA after the lead-in period BSA (m2) Viramune prolonged-release tablets dose (mg) 0.58-0.83 200 (2 x 100 mg) 0.84-1.16 300 (3 x 100 mg) 400 (1 x 400 mg)
Maltese: Dożaġġ pedjatriku rakkomandat skont il-BSA wara l-perjodu ta' introduzzjoni BSA (m2) Doża ta' Viramune pilloli li jerħu l-mediċina bil-mod (mg) 0.58-0.83 200 (2 x 100 mg) 0.84-1.16 300 (3 x 100 mg) 400 (1 x 400 mg)
English: Nevirapine: there was no significant difference in nevirapine pharmacokinetic parameters.
Maltese: Nevirapine: ma kienx hemm differenza sinifikanti fil-parametri farmakokinetiċi ta' nevirapine.
English: Randomisation was stratified by screening HIV-1 RNA level (<100,000 copies/ml and >100,000 copies/ml).
Maltese: Il-każwalità ġiet stratifikata bl-iscreening tal-livell ta' HIV-1 RNA (<100,000 kopji/ml u >100,000 kopja/mL).
English: Maraviroc AUC  1.01 (0.6 -1.55) Maraviroc Cmin ND Maraviroc Cmax  1.54 (0.94-2.52) compared to historical controls
Maltese: Maraviroc AUC  1.01 (0.6 -1.55) Maraviroc Cmin ND Maraviroc Cmax  1.54 (0.94-2.52) meta mqabbla ma' kontrolli storiċi
English: Viramune contains lactose
Maltese: Viramune fih lactose
English: Each tablet contains 318 mg of lactose (as monohydrate).
Maltese: Kull pillola fiha 318 mg ta' lactose (bħala monohydrate).
English: In an open-label clinical study (ACTG 180) granulocytopenia assessed as medicinal product-related occurred in 5/37 (13.5 %) of patients.
Maltese: Fi studju kliniku open-label (ACTG 180) granuloċitopenija assessjata bħala relatata mal-prodott mediċinali seħħet f'5/37 (13.5%) pazjent.
English: Other medicines and Viramune
Maltese: Mediċini oħra u Viramune
English: Each bottle contains 2.4 g of nevirapine (as hemihydrate) in 240 ml of Viramune oral suspension.
Maltese: Kull flixkun fih 2.4 g ta' nevirapine (bħala hemihydrate) f'240 ml ta' Viramune suspensjoni orali
English: Table 4: Summary of lipid laboratory values at baseline (screening) and week 48 - study
Maltese: Tabella 4: Sommarju tal-valuri tal-laboratorju tal-lipidi fil-linja bażi (screening) u ġimgħa 48studju 1100.
English: Emtricitabine is not an inhibitor of human CYP 450 enzymes.
Maltese: Emtricitabine mhuwiex inibitur ta' enzimi umani ta' CYP 450.
English: Telaprevir is metabolised in the liver by CYP3A and is a P-glycoprotein substrate.
Maltese: Telaprevir jiġi metabolizzat fil-fwied minn CYP3A u hu subtrat ta' Pglikoproteina.
English: Pharmacotherapeutic group: Antivirals for systemic use, non-nucleoside reverse transcriptase inhibitors, ATC code J05AG01.
Maltese: Mediċini antivirali għal użu sistemiku, non-nucleoside reverse transcriptase inhibitors, Kodiċi ATC:
English: NN {number} [national reimbursement number or other national number identifying the medicinal product]
Maltese: NN {numru} [numru tar-rimborż nazzjonali jew numru nazzjonali tal-identifikazzjoni ieħor għallprodott mediċinali]
English: Data reported in the literature from 20 HIV-infected patients suggest a steady state Cmax of 5.74 µg/ml (5.00-7.44) and Cmin of 3.73 µg/ml (3.20-5.08) with an AUC of 109.0 h*µg/ml (96.0-143.5) in patients taking 200 mg of nevirapine bid.
Maltese: Skont data pubblikata fuq 20 pazjent infettati b'HIV, l-valur Cmax ta' nevirapine waqt ekwilibriju kien ta' 5.74 µg/ml (5.00-7.44) u ta' Cmin kien ta' 3.73 µg/ml (3.20-5.08), b'AUC ta' 109.0 h*µg/ml (96.0-143.5), meta ngħataw ammont ta' 200 mg nevirapine.
English: Week 48 (mean) n=419
Maltese: Ġimgħa (medja) n=419
English: Clinical hepatitis reported as clinical adverse event occurred in 10 (2.6 %) and 2 (0.5 %) patients in the nevirapine twice daily and efavirenz groups respectively.
Maltese: Epatite klinika rapportata bħala każ avvers kliniku seħħet f'10 (2.6%) u 2 (0.5%) pazjenti fil-gruppi ta' nevirapine li ngħata darbtejn kuljum u ta' efavirenz rispettivament.
English: - or have a body surface area above 1.25 square metres.
Maltese: - li għandhom erja superfiċjali 'l fuq minn 1.25 metri kwadri.
English: Hypersensitivity (anaphylactic reaction, angioedema and urticaria) have been reported.
Maltese: Ġew rapportati sensittività eċċessiva (reazzjoni anafilattika, anġjoedema u urtikarja).
English: Nevirapine in combination with efavirenz exhibited a strong antagonistic anti-HIV-1 activity in vitro (see section 4.5) and was additive to antagonistic with the protease inhibitor ritonavir or the fusion inhibitor enfuvirtide.
Maltese: Nevirapine f'kombinazzjoni ma' efavirenz wera attività antagonistika qawwija kontra l-HIV-1 in vitro (ara sezzjoni 4.5) u kien addittiv sa antagonistiku mal-inibitur tal-protease ritonavir jew l-inibitur fużjonali enfuvirtide.
English: When rash occurs it is normally mild to moderate.
Maltese: Meta jiżviluppa r-raxx dan hu normalment minn ħafif sa moderat.
English: Geometric mean steady-state plasma Viramune prolonged-release pre-dose trough concentrations were 3,880 ng/ml, 3,310 ng/ml and 5,350 ng/ml in age groups 3 to <6 years, 6 to <12 years, and 12 to <18 years of age, respectively.
Maltese: Il-medja ġeometrika tal-konċentrazzjonijiet minimi ta' qabel id-doża ta' Viramune li jerħi l-mediċina bil-mod fil-plażma fl-istat fiss kienet ta' 3,880 ng/ml, 3,310 ng/ml u 5,350 ng/ml filgruppi ta' età minn 3 sa <6 snin, 6 sa <12-il sena, u 12 sa <18-il sena, rispettivament.
English: The anti-HIV-1 activity of nevirapine was antagonized by the anti-HBV medicinal product adefovir and by the anti-HCV medicinal product ribavirin in vitro.
Maltese: L-attività kontra HIV-1 ta' nevirapine kienet antagonizzata bil-prodott mediċinali kontra l-HBV adefovir u bil-prodott mediċinali kontra l-HCV ribavirin in vitro.
English: Nevirapine metabolites: Studies using human liver microsomes indicated that the formation of nevirapine hydroxylated metabolites was not affected by the presence of dapsone, rifabutin, rifampicin, and trimethoprim/sulfamethoxazole.
Maltese: Studju fuq mikrożomi tal-fwied tal-bniedem indika li l-produzzjoni ta' metaboliti hydroxylated ta' nevirapine ma kienux affettwati bil-preżenza ta' dapsone, rifabutin, rifampicin, u trimethoprim/sulfamethoxazole.
English: Viramune tablets are supplied in blisters, with 14, 60 or 120 tablets per carton.
Maltese: Il-pilloli Viramune jiġu f'folji, b'14, 60 jew 120 pillola f'kull kartuna.
English: Nevirapine exhibited additive to synergistic anti-HIV-1 activity in combination with the protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, saquinavir and tipranavir, and the NRTIs abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir and zidovudine.
Maltese: Nevirapine wera attività addittiva sa sinerġistika kontra l-HIV-1 flimkien ma' l inibituri ta' protease, amprenavir, atazanavir, indinavir, lopinavir, saquinavir u tipranavir, u l-NRTIs abacavir, didanosine emtricitabine, lamivudine, stavudine, tenofovir u zidovudine.
English: John‘s Wort check nevirapine and if possible viral levels and stop St.
Maltese: John‘s Wort iċċekkja l-livell ta' nevirapine u jekk possibbli l-livelli virali u waqqaf St.
English: The overall incidence of adverse events was significantly lower (61 patients, or 41 %) in the abacavir group than in the nevirapine group (83 patients, or 54 %) or the efavirenz group (89 patients, or 57 %).
Maltese: L-inċidenza globali ta' każijiet avversi kienet sinifikament inqas (61 pazjent, jew 41%) fil-grupp ta' abacavir milli fil-grupp ta' nevirapine (83 pazjent, jew 54%) jew fil-grupp ta' efavirenz (89 pazjent, jew 57%).
English: - Other**
Maltese: - Oħrajn**
English: Viramune prolonged-release n=508*
Maltese: Viramune li jerħi l-mediċina bilmod n=508*
English: The simultaneous use of nevirapine (400 mg) plus efavirenz (800 mg) was associated with the highest frequency of clinical adverse events and with the highest rate of treatment failure (53.1 %).
Maltese: L-użu f'daqqa ta' nevirapine (400 mg) flimkien ma' efavirenz (800 mg) kien assoċjat mal-ogħla frekwenza ta' każijiet avversi kliniċi u mal-ogħla rata ta' falliment fil-kura (53.1%).
English: Genotypic analysis of isolates from antiretroviral naïve patients experiencing virologic failure (n=71) receiving nevirapine once daily (n=25) or twice daily (n=46) in combination with lamivudine and stavudine for 48 weeks showed that isolates from 8/25 and 23/46 patients, respectively, contained one or more of the following NNRTI resistance-associated substitutions: Y181C, K101E, G190A/S, K103N, V106A/M, V108I, Y188C/L, A98G, F227L and M230L.
Maltese: L-analiżi ġenotipika ta' kampjuni minn pazjenti inkonsapevoli għal antiretrovirali li esperjenzaw falliment viroloġiku (n=71) li qegħdin fuq nevirapine darba kuljum (n=25) jew darbtejn kuljum (n=46) f'kombinazzjoni ma' lamivudine u stavudine għal 48 ġimgħa wriet li kampjuni minn 8/25 u 23/46 pazjent, rispettivament, kien fihom wieħed jew aktar mis-sostituzzjonijiet li ġejjin assoċjati mar reżistenza ta' NNRTI: Y181C, K101E, G190A/S, K103N, V106A/M, V108I, Y188C/L, A98G, F227L u M230L.
English: Nevirapine belongs to a class of anti-HIV medicines called non-nucleoside reverse transcriptase inhibitors (NNRTIs).
Maltese: Nevirapine jappartjeni għal kategorija ta' mediċini li jaħdmu kontra l-HIV imsejħa non-nucleoside reverse transcriptase (NNRTIs).
English: Viramune oral suspension contains 162 mg sorbitol per ml.
Maltese: Is-suspensjoni orali Viramune fiha 162 mg ta' sorbitol kull ml.
English: Fosamprenavir/ritona vir 700/100 mg BID
Maltese: Fosamprenavir/ ritonavir 700/100 mg BID
English: Rifabutin 150 or 300 mg QD
Maltese: Rifabutin 150 jew 300 mg QD
English: In a panel of 2,923 predominantly subtype B HIV-1 clinical isolates, the mean EC50 value was 90nM.
Maltese: F'panew ta' 2,923 kampjun kliniku li prinċipalment kienu HIV-1 minn sottotip B, il-valur medju ta' EC50 kien ta' 90nM.